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AT1 angiotensin receptor plays important physiological and pathophysiological roles in
the cardiovascular system. Renin-angiotensin system represents a target system for
drugs acting at different levels. The main effects of ATR1 stimulation involve activation
of Gq proteins and subsequent IP3, DAG, and calcium signaling. It has become evident
in recent years that besides the well-known G protein pathways, AT1R also activates
a parallel signaling pathway through β-arrestins. β-arrestins were originally described
as proteins that desensitize G protein-coupled receptors, but they can also mediate
receptor internalization and G protein-independent signaling. AT1R is one of the most
studied receptors, which was used to unravel the newly recognized β-arrestin-mediated
pathways. β-arrestin-mediated signaling has become one of the most studied topics in
recent years in molecular pharmacology and the modulation of these pathways of the
AT1Rmight offer new therapeutic opportunities in the near future. In this paper, we review
the recent advances in the field of β-arrestin signaling of the AT1R, emphasizing its role
in cardiovascular regulation and heart failure.
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INTRODUCTION
AT1 angiotensin II receptor (AT1R) belongs to the G protein-coupled receptor (GPCR) family
of membrane receptors and is activated by the octapeptide hormone, angiotensin II (AngII).
AngII is the main effector of the renin-angiotensin system (RAS), which has pleiotropic
effects in the cardiovascular system and salt-water balance regulation. As such, the RAS
is an important target in the treatment of various cardiovascular diseases. AT1R blockers
(ARBs) and angiotensin-converting enzyme inhibitors are widely used for the treatment of
hypertension. Moreover, ARBs have beneficial effects beyond lowering the blood pressure,
by preventing cardiovascular organ injuries (1). AngII can bind and activate two types
of angiotensin receptors (type 1 and type 2 angiotensin receptors). Some cells contain
AT2-receptors that mostly act via Gi and tyrosine phosphatases showing somewhat opposite
effects to the AT1R-mediated cellular responses (2). However, the main physiological and
pathological effects of RAS are mediated by AT1R. Initially, G protein activation was
considered to be the only signal transduction process, which mediates the effects of AngII
via AT1R. After AngII binding to AT1R, a heterotrimeric G protein, Gq mediates the
hydrolysis of PtdIns(4,5)P2 by phosphoinositide-specific phospholipase Cβ resulting in a
generation of second messengers. In addition, AT1R can also couple to Gi/o and G12/13
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proteins leading to inhibition of adenylyl cyclase, activation
of phospholipase D, Rho-kinase, and regulation of Ca2+
channels (3, 4).
Following their activation, GPCRs usually undergo G
protein kinase (GRK) dependent phosphorylation on serine
and threonine residues on their C-terminal tails. This
phosphorylation leads to binding of β-arrestin proteins,
which shut down G protein activation and target the receptors
toward internalization. During the last two decades it became
increasingly evident that, in addition to G proteins, β-arrestins
can also mediate signaling events. β-arrestin proteins serve
as scaffold proteins, bringing together the players of different
protein kinase cascades, and instead of turning it off, they
switch the signaling toward different routes (5). Like many other
GPCRs, AT1R also binds β-arrestins, and β-arrestins regulate
their internalization (6–8) Since the recognition of the role of
β-arrestins in AT1R internalization, AT1R served as one of the
most studied model for β-arrestin-dependent signaling, which
has led to a completely new field in molecular pharmacology
with the potential of development of new drugs, which may
exploit the possibilities in selective activation of GPCR-activated
signaling pathways.
STRUCTURAL REQUIREMENTS FOR
INTERNALIZATION AND β-ARRESTIN
BINDING TO THE AT1R
The binding of agonists to G protein-coupled receptors
initiate the “classical,” G protein-mediated pathway, which
results in the production of second messenger molecules.
Termination of signaling has a key role in the regulation of the
kinetics of receptor function. Mechanisms regulating receptor
function include several consecutive or parallel processes, such
as desensitization, internalization into intracellular vesicles,
and degradation of the receptors. Receptor internalization is
regulated by phosphorylation by GPCR kinases, which promotes
the β-arrestin binding leading to desensitization, internalization
and altered signaling of GPCRs (9). The role of a serine-threonine
rich domain in the C-terminus of AT1R for angiotensin
receptor internalization was first described in the laboratory
of Kevin J. Catt (10–12). It was initially discovered with
mutational and truncation analysis of AT1R that Thr332-Lys333-
Met334-Ser335-Thr336-Leu337-Ser338 amino acids, particularly
the Ser335-Thr336-Leu337 motif on the C-terminus of the
receptor are required for receptor internalization (10). A large
number of serine and threonine amino acids in this region
suggested the possible involvement of phosphorylation in its
regulation. Indeed, Thr332, Ser335, Thr336, and Ser338 amino
acids have been later identified as phosphorylation sites that
regulate endocytosis (12–14), and involvement of β-arrestins in
receptor internalization was verified (6, 15). The same serine
and threonine amino acids were identified as the region critical
for stable interaction between AT1R and β-arrestins following
AngII stimulation (15, 16). On β-arrestin, two critical lysins
(K11 and K12 in β-arrestin2), the phosphate-binding residues,
are responsible for the stable interaction (17–22). It turns out,
that the interaction between the serine/threonine-rich region
and these two lysins (the “stability lock”) is responsible for the
conformational rearrangement in βarrestin2 protein, leading to
recruitment of the members (23, 24) and activation of ErkMAPK
cascade (16). Interestingly, not only receptor activation, but also
PKCmediated phosphorylation of the inactive, unliganded AT1R
alone leads to recruitment of β-arrestin2, receptor internalization
and scaffolding of the signaling complex (24).
THE CONCEPT OF BIASED AGONISM
Ligand binding to a plasma membrane receptor can initiate
several parallel signal transduction pathways leading to various
responses in the cell. Ligands of the plasma membrane receptors
were originally classified as agonists and antagonists (or more
recently inverse agonists). However, several ligands are capable of
selectively initiating one or more of distinct signal transduction
pathways coupled to one receptor, which phenomenon has been
referred to as “biased agonism” or “functional selectivity.” It has
been revealed that the biased agonism is an important feature of
several members of the GPCR superfamily, and it is proposed
that the biased agonists can serve as new therapeutic agents
(25). Some of the GPCR ligands can selectively couple the given
receptor to the different downstream signaling events, including
G protein activation and β-arrestin-mediated signaling, leading
to altered signaling patterns compared to the natural agonist.
The background of this phenomenon is that the variant ligands
cause distinct conformational changes in the structure of the
receptor. The different conformations can lead to dissimilar
interaction capabilities with G proteins and to other partners.
Another layer of complexity is introduced by the recognition of
different phosphorylation patterns on the receptor C-terminus.
It has been recognized, that different receptors bind arrestins
with different affinities, some of which form stable (called class
B receptors) whereas others form loose interactions with β-
arrestins (called class A receptors) (26). Interaction stability
and arrestin activation seem to be determined by specific
patterns of phosphorylated serine/threonine amino acids (22,
27). Moreover, different kinases may phosphorylate different
residues on the C-terminus, resulting in slightly different
outcomes regarding internalization, signaling and activated β-
arrestin conformations. This phenomenon has led to the barcode
theory. Slightly different active receptor conformations, different
cellular expression contexts, or even simultaneous stimulation
of other receptors can lead to altered phosphorylation patterns,
leading to different conformations of β-arrestins, and altered
signaling (28–34). AT1R phosphorylation by GRK2/3 regulates
receptor endocytosis, while phosphorylation by GRK5/6 activates
Erk1/2 (35). Even PKC phosphorylation can initiate β-arrestin
binding and recruitment of the MAPK machinery to the AT1R,
although the binding affinity is lower and the active conformation
of the β-arrestin is altered (24). These data together suggest,
that signaling bias is not restricted to the G-protein-β-arrestin
axis, but even β-arrestin dependent signaling may be finely tuned
toward distinct outcomes depending on the actual stimulation
and cellular context.
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Early studies had identified mutant receptors of the highly
conserved Asp125Arg126Tyr127 sequence of AT1R (i.e.,
DRY/AAY mutation), which are not able to couple to G proteins,
but still capable to internalize and bind β-arrestins (7, 36). Using
this mutant AT1R, it has been demonstrated that AT1R can
cause ERK 1/2 phosphorylation or Src activation in the absence
of G protein activation (7, 37, 38). Furthermore, a biased AT1R
agonist, [Sar1,Ile4,Ile8]-AngII (SII-AngII) was developed, which
is a mutated octapeptide angiotensin analog unable to activate
Gq-proteins, but still recruits β-arrestins to the AT1R and is able
to evoke the internalization of the receptor (39). Thus, it acts
as a biased agonist, which selectively activates β-arrestins. This
octapeptide further widened the possibilities to investigate G
protein-independent mechanisms. It has been shown, that this
agonist can also stimulate G protein-independent mechanisms
(7). It was proposed that G protein-mediated MAP kinase
activation regulates nuclear targets, while the β-arrestin-
mediated MAP kinases activation affects the phosphorylation
of cytoplasmic proteins (40, 41). Also, compared to G-protein-
dependent Erk1/2 activation, β-arrestin-dependent Erk1/2
signaling is slower, reaching its maximum after 10min and
remains active for a prolonged time (40). Later, several new
AngII peptide analogs have been developed and characterized
with a bias toward G protein or β-arrestin signaling (42–44). The
discovery of the biased signaling has led to the recognition that
AT1R may develop multiple active conformations, and this has
been demonstrated by molecular dynamics simulations (45, 46)
and experimentally (47–49). Conformational changes within
AT1R may be followed with BRET sensors utilizing a small
molecule acceptor (FlAsH molecule). When placed on different
places within AT1R, different conformational changes following
stimulation with distinct ligands can capture multiple activation
states of the receptor (47). Different conformational states after
binding of the different ligands have been further demonstrated
using single molecular spectroscopy (48) and more recently
using double electron-electron resonance spectroscopy in AT1R
(49). The developed biased agonists serve now as widely used
tools to study the biased agonism of the AT1R, and numerous of
their effects on cell responses were published in recent years (50).
SIGNALING PATHWAYS REGULATED BY
AT1R THROUGH β-ARRESTIN
β-arrestin-mediatedmechanisms can be considered as the second
wave of signal transduction events resulting in alternative
outcomes. Moreover, the agonist binding of AT1R can lead to
direct association with wide spectra of cytoplasmic signaling
proteins, such as AT1R-associated protein (ATRAP), SHP-2,
JAK2, β-arrestins, and phospholipase Cγ, which explains a
plethora of AT1R generated signaling mechanisms, including
JAK/STAT pathway and MAPK cascade activation (51–54). The
attached proteins can initiate diverse cellular responses from
the receptor-arrestin complex and can form multiprotein units,
“signalosomes” (55).
One such selectively activated pathway of particular interest
is the β-arrestin-dependent signaling. β-arrestin-mediated
signaling events include activation of Src tyrosine kinases
extracellular signal-regulated kinase 1/2 (ERK 1/2), c-Jun
N-terminal kinase (JNK), mitogen-activated protein kinase
(MAPK) cascades, Akt and p38 mitogen-activated protein
kinases (56–59).
Besides the observation of Erk1/2 activation through β-
arrestins, many other cellular functions have been discovered
to be regulated through GPCRs in a non-canonical G protein-
independent way. These pathways include JNK3, p38, and Akt
protein kinase regulation (56), some of which have been also
implicated in AT1R signaling (60, 61). The pathways may include
very broad signaling routes, including the increased protein
synthesis via β-arrestin-mediated Mnk1, eIF4E, and ERK1/2
activation (62). The arrestin-biased ligand, SII-AngII is also
able to increase the aldosterone synthesis in adrenocortical zona
glomerulosa cells via β-arrestin, in addition to the AngII-induced
Gq protein-dependent aldosterone production, which can lead
to adverse cardiac remodeling and heart failure progression
(63). Several proteomic and genetic studies were carried out to
investigate the short and long term effects of the treatment of
SII-AngII using both AT1R overexpressing cells and primary
cell cultures. It has been demonstrated that the SII-AngII could
initiate a robust G protein-independent signaling network, and
signaling pathways significantly differ than the AngII induced
cellular responses. Kendall et al. demonstrated that the SII-
AngII treatment changed the phosphorylation state of numerous
downstream proteins, such as protein phosphatase 2A and
prostaglandin E synthase 3 (64). The inhibitory phosphorylation
of protein phosphatase 2A results in Akt activation and
phosphorylation of glycogen synthase kinase 3β, whereas the
prostaglandin E synthase 3 activation increases prostaglandin
production both in AT1R expressing HEK293 cells and in rat
aortic vascular smooth muscle cells (64). It is very astonishing
that the SII-AngII-induced phosphorylation patterns have
limited overlap with those of AngII-induced phosphorylation
(64), suggesting that the β-arrestin activation initiates not
only spatially, but also qualitatively different signaling events.
Analyzing the β-arrestin-mediated phosphoproteome after SII
stimulation of AT1R revealed a plethora of changes in
protein phosphorylation, including a huge number of kinases
and some phosphatases as well (65). Besides the activation
of different kinase cascade signaling pathways, β-arrestin-
dependent regulations of ion channels have been also reported
following AT1R activation, including TRPV4 (66), TRPC3 (67),
and CaV1.2 (68) channels.
ROLE OF THE β-ARRESTIN DEPENDENT
AT1R SIGNALING IN CARDIAC FUNCTION
AND HEART FAILURE (HF)
Since the AngII is a vasopressor hormone, its production and
effects are very important in the development of numerous
cardiovascular diseases such as hypertension, atherosclerosis, and
cardiac hypertrophy. Indeed, AT1R blockers and inhibitors of
AngII production (ACE inhibitors) are now extensively used in
the treatment of hypertension and other cardiovascular diseases
Frontiers in Endocrinology | www.frontiersin.org 3 August 2019 | Volume 10 | Article 519
Turu et al. Arrestin Role in AT1R Function
(69, 70). Special fields of interest, where RAS plays significant
roles are cardiac hypertrophy and heart failure, where AngII
seems to contribute to the pathophysiology of these conditions.
Both AT1R-activation of G protein-dependent and G
protein-independent mechanisms contribute to the development
of cardiac hypertrophy. It was demonstrated that heart-
specific overexpression of different AT1R mutants can lead
to hypertrophy, moreover, the mutant AT1R, which mediates
only G protein-independent signaling mechanisms, caused
greater cardiac hypertrophy but less apoptosis and fibrosis than
overexpression of wild-type AT1R (71). Contrary, in vascular
smooth cells (VSMCs) only the G protein-dependent mechanism
of AT1R, mediated by EGF receptor transactivation and Rho
kinase activation, seems to be important in AngII-induced
hypertrophy (72). However, β-arrestin 1 dependent activation of
RhoA has been demonstrated as well, and interaction of AT1R
with SHP2 through Y319 residue might be involved in EGF
receptor transactivation (73, 74). Interestingly, with wild type
AT1Rs, cardiac hypertrophy was reported to be dependent on G
protein and metalloprotease activation but did not occur after β-
arrestin biased SII-AngII stimulation of AT1Rs (75). According
to Aplin et al., the G protein-independent signaling supports the
non-hypertrophic proliferation of rat cardiomyocytes (76, 77).
In the development of pathological cardiac hypertrophy,
mechanical stress is thought to be one of the most important
factors. Parallel with the discoveries of the β-arrestin-dependent
signaling through AT1R, AT1R receptor was also found to be
involved in stretch-induced signaling pathways in various cell
types. First, it has been discovered, that in cardiomyocytes,
stretch-induced Erk1/2 activation was dependent on AT1Rs (78–
80). Since then, many further papers have been published with
observations of mechanical stretch-induced, AT1R-mediated
signaling in different cell types, including cardiomyocytes (81–
85), vascular smooth muscle cells (86–89), renal podocytes (90),
endothelial (91), and epidermal cells (92).
Interestingly, mechanical activation of AT1R caused increased
affinity toward β-arrestin biased ligand TRV 120023 (93),
suggesting stabilization of a biased active receptor conformation.
Moreover, protein kinase C and GRK2, the kinase responsible
for phosphorylation and subsequent β-arrestin binding of many
GPCRs, has been reported to be activated upon stretch in
neonatal rat ventricular myocytes (94). Indeed, hypo-osmotic
stretch and mechanical stress induced β-arrestin translocation
to the AT1R (88, 95). It turns out that EKR1/2 activation by
mechanical stress through AT1R is β-arrestin dependent (95).
Stretch-induced β-arrestin-dependent signaling may involve
Erk1/2, Akt kinases, EGFR transactivation (92, 95), and Src may
also play an important role in this process (96). In line with the
very recent developments (see below), mechanically activated β-
arrestin signaling may also involve the activation of Gi/o proteins
through AT1R (97).
The involvement of AT1R- β-arrestin interplay in cardiac
function has become more evident with the discovery of
the beneficial effects of biased AT1R ligands on the heart
contractility. RAS is typically activated in patients with HF,
with increased circulating AngII levels. Anti-RAS drugs, like
AT1R blockers and ACE inhibitors, have been long proven
beneficial in the treatment of HF. It seems that the pathological
actions of AT1R on vasoconstriction and heart remodeling
are mediated through Gq-protein activation. On the contrary,
studies have suggested that TRV120023 and TRV120027, a
β-arrestin biased ligand of AT1R, decrease blood pressure
similarly to AT1R blockers, but unlike those drugs, it improves
cardiac performance, preserves cardiac stroke volume, decreases
systemic vascular resistance, improves cardiac output while
preserving renal functions in animal models (44, 98).
Moreover, TRV120027, in combination with furosemide,
decreased preload and afterload in dog models of HF, while
furosemide-induced natriuresis and diuresis were preserved
(98). Infusion of biased AT1R ligand TRV120023 into mice
with familial dilated cardiomyopathy increased myosin light-
chain phosphorylation and improved cardiac contractility (99).
Earlier studies have already shown, that SII-AngII treatment can
lead to increased cardiomyocyte inotropy and lusitropy (100),
and in line with that, Frank-Starling mechanism of the heart,
which describes the volume load-contractility relationship of the
heart, has been found to be dependent both on AT1R and β-
arrestins (101). Besides Ca2+ sensitization, in immature mouse
cardiomyocytes, TRV120027 activates CaV 1.2 Ca2+ channels as
well through Src-family tyrosine kinases and casein kinase 2 in a
β-arrestin-dependent manner (102).
After the initial promising results with biased AT1R ligands
on the heart function, the first human study was reported in
2013 (103) and in the same year, the phase IIb study was
initiated in patients with acute HF, and the results were reported
in 2017 (104). Unfortunately, the results of this study did not
confirm the beneficial effects of the biased AT1R activation,
in fact, in none of the primary endpoints was observed an
improved outcome. However, in this study, short time therapy
was assessed; the patients were treated for only 48–96 h after
within 24 h of initial presentation, and then the outcomes of
acute heart failure were investigated. TRV120027 itself is an
octapeptide, which has a half-life of only about a few minutes,
so it has to be administered intravenously, and this restricts
its long-time usability in patients. Therefore, although this
study failed to justify the use of biased AT1R ligands in HF
failure therapy, long-term treatment may be still beneficial.
Indeed, a recent study on dilated cardiomyopathy mouse
model showed improved cardiac structure and function after 3
months of TRV120067, another biased AT1R ligand treatment
(105). However, TRV120067 is also a peptide, which limits its
application in human patients in long-term therapy plans. The
use of small molecules having β-arrestin biased activity on AT1R
might be beneficial, however, to date, only one such molecule
has been reported. Although troglitazone is a small molecule,
potentially suitable for long-term treatments, this molecule has a
very weak affinity toward AT1R, making it unattractive in in vivo
experiments (106).
Although these experiments have very promising results,
some important aspects of the RAS are often overlooked which
may influence the in vivo results. It is widely accepted now,
that AT1R can form heterodimers with other GPCRs, and the
function of the heterodimers might be influenced by the active
state of the AT1R. A classic example of interaction is bradykinin
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B2 receptor, but there are also other examples of interactions
(38, 107–117). In HEK293 cells, SII-AngII inhibits B2 receptor-
mediated Gq/11-dependent intracellular calcium influx when
AT1R is coexpressed, showing that AT1R-biased ligands effects
might be mediated not only by β-arrestins, but also by more
complex interactions between different GPCRs (118). Another
often overlooked aspect of the biased ligand actions is the
presence of the other angiotensin II receptor in vivo, the AT2
angiotensin receptor (AT2R). Although the AT2R does not bind
β-arrestins upon Ang II stimulation (119), it still may play role in
in vivo effects of the AT1R biased agonists. SII-AngII, TRV120023
and TRV120027 seem to bind to this receptor as well, but
their effects were mediated through AT1R in experiments where
AT2 receptors were checked (44, 120, 121). However, to our
knowledge, the effects of these ligands have not been thoroughly
tested on AT2R.
In any case, with the better understanding of the AT1R
conformation upon biased activation (45–49), and the readily
availability of bioinformatical tools in drug screening (122), the
discovery of high affinity drugs with small molecular weight
might not be that far.
IS β-ARRESTIN SIGNALING
G PROTEIN-INDEPENDENT?
Originally, β-arrestin-mediated signaling was thought to be
independent of G protein activation. In fact, AT1R-activated
pathways have been usually divided into G protein-dependent
and G protein-independent (e.g., β-arrestin-dependent), since
AT1R mutants used in the studies and biased AT1R ligands
failed to activate the usual Gq-protein signaling with IP3 and
DAG production and consequent Ca2+ signal generation. It
has challenged the concept of the clean β-arrestin dependent
Erk1/2 activation when SII-AngII, the most widely used β-
arrestin biased ligand, has been shown to activate Gq and
Gi proteins, however with much weaker efficacy then AngII
(123). In addition, this Erk1/2 activation was dependent on
G protein activation. Similarly, the mechanic stretch-induced
activation of Erk1/2 signaling seems to be also Gi-dependent,
although in this setup, β-arrestin biased ligands (TRV12023
and TRV12026) did not require Gi coupling (97). However,
very recently, using pathway-wide BRET signaling sensors, 14
different AT1R ligands have been tested, including the β-arrestin
biased ones, such as TRV120027. Strikingly, all of the tested
ligands activated Gi and G12 proteins with some efficacy (124),
raising the possibility that some β-arrestin-dependent signaling
pathways may utilize one or more G protein-dependent signaling
mechanisms. Indeed, another recent study has used CRISPR-
Cas9 system to switch off all G proteins, including G12/13 and
used PTX to inhibit Gi (“zero functional G” setup) (125). They
found, that although β-arrestin still couples to a set of GPCRs,
with no functional G proteins, the Erk1/2 could not be activated.
On the other hand, CRISPR deletion of β-arrestin1/2 results in
various effects on Erk1/2 signaling, depending on the cell line
and receptor type, it may be enhanced, inhibited or unchanged
(126). These data show that the picture of β-arrestin-mediated
signaling is more complex than we originally thought. The
cellular background, adaptive mechanisms, β-arrestin’s dual role
(desensitization and activation of β-arrestin-dependent Erk1/2
signaling) lead to a very complex regulation mechanism where
the end-effect on the signaling cascade will be determined on
the interplay of these aspects (126). The available data suggest
that during β-arrestin-signaling a complex interplay occurs
between β-arrestin-signaling and kinase cascades. This model
could explain the recent developments of the field. Although
β-arrestin sequestrates together with all the components of
the cRaf/MEK/Erk1/2 cascade, the activation of the most
proximal kinase in the cascade may be kicked on by
β-arrestin-independent mechanisms, which might be either a G
proteins, or in more physiological settings, one of the classical,
growth factor receptors (56, 127). So far, at least three different
FIGURE 1 | Possibilities of β-arrestin recruitment. β-arrestins are recruited to the AT1R either by activation by ligand or stretch, or by PKC-dependent phosphorylation
of the unliganded receptor.
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mechanisms may lead to β-arrestin coupling to the AT1R, the
classical ligand-dependent way, mechanical stretch and PKC
activation (Figure 1). When no other stimulus is present, β-
arrestins might not be able to activate the most proximal
kinases, but when they are already activated, it brings together
all the pieces of the signaling cascade and orchestrates their
spatiotemporal regulation.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
We have come a long way in the recent almost 20 years since
the interaction of AT1R and β-arrestin has been discovered.
The interaction of these two proteins itself had a huge
effect in understanding how the GPCRs function, and how
are the signaling pathways regulated beside the classical G
protein activation. We are at the doorstep of therapeutic
exploitation of this system, and although the first attempt to
cross it was not successful, recent results suggest that this was
probably not our last chance. Recent advances in the field also
show that there might be still a lot learn about β-arrestin-
dependent signaling, and AT1R might further serve as a good
model for such experiments.
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